DNA Software Receives the 2023 Technology Innovation Leadership Award

DNA Software has been identified as best in class in the North American multiplex PCR solutions industry.

Frost & Sullivan applies a rigorous analytical process to evaluate multiple nominees for each Award category before determining the final Award recipient. The process involves a detailed evaluation of best practices criteria across two dimensions for each nominated company. DNA Software excels in many of the criteria in the multiplex polymerase chain reaction solutions space.

Multiplex Polymerase Chain Reaction: Market Overview

Pharmaceuticals and biotechnology companies consider polymerase chain reaction (PCR) the gold standard for modern diagnostics. Unlike conventional singleplex PCR, multiplex PCR simultaneously detects multiple targets in a single reaction well. As a result, Frost & Sullivan notes that its advantages include cost effectiveness, timesaving, higher throughput, increased data normalization accuracy, reduced pipetting errors, and deriving more information with a smaller sample.

However, multiplex panel designs must ensure accuracy to avoid false negatives. Technique limitations include insufficient models and knowledge regarding hyrbidization, suboptimal tools (design freeware), and advanced algorithms operating on inadequate information technology infrastructure. DNA Software™ (DNAS) uniquely leverages its expertise to meet customer needs. Frost & Sullivan analysts observe that the company is well-positioned to capitalize on new growth opportunities, cementing its position in the multiplex PCR solutions market.

A Commitment to Innovation and Creativity

Founded in 2000 and headquartered in Michigan, the United States (US), DNAS is a deoxyribonucleic acid (DNA) diagnostic design and analysis solutions provider. The company has helped hundreds of organizations overcome challenges and increased clients’ time-to-market through its cutting-edge multiplex software. In 2019, Frost & Sullivan recognized DNAS for its multiplex software, reflecting cloud computing, modern algorithms, and a deep understanding of PCR mechanisms, and remains impressed © Frost & Sullivan 2023 The Growth Pipeline Company™
with the company’s continuing innovation and recent offering of pre-validated PCR kits. DNAS recognizes unmet client needs and ensures that it develops solutions truly meeting customer and market demands. Burgeoning from the renowned scientist Dr. John SantaLucia Junior’s laboratory at Wayne State University, the company nurtures a research-focused culture propelling innovation. The team includes world-leading DNA and ribonucleic acid (RNA) biophysical chemistry experts who develop best-in-class algorithms for predicting hybridization and folding. As a result, DNAS’ technology accelerates the discovery process from months to minutes – saving an impressive 80% of research and developmentrelated resources.

Its software offerings include:

• OMP-DE™: The Oligonucleotide Modeling Platform is DNAS’ programmable predictive modeling environment that forms the core of its product line. OMP encapsulates the company’s chemical and biological data into a single design and simulation PCR script software platform.
• ThermoBLAST™: Addresses primer specificity by scanning multiple primers against genome collections to find all hybridizations and amplicons. Unlike the traditional BLAST, it captures critical mishybridization hits through appropriate thermodynamic scoring based on complementarity as opposed to similarity, displaying all false amplicons, considering extensibility and stable mismatches, and allowing for solution conditions, buffers, salt, additives, and other experimental factors.
• CopyCount™: A breakthrough in understanding quantitative (q) PCR, the product allows for the absolute quantifying of qPCR, eliminating the need for a standard curve, excessive replicates, or sample dilution. As a result, CopyCount saves time and money, generates easy-to-interpret results, and is compatible with existing qPCR instrumentation.
• Visual OMP™: Desktop software for visualizing and simulating assay artifacts.
• PanelPlex™: The multiplex PCR design software for cancer panels, anti-microbial resistance, and other applications has been rigorously validated for detecting diverse bacteria, viruses, and human targets. It saves an average of six to nine months of iterative experimental trial-and-error optimization, produces diagnostic quality designs and automated consensus designs of multiple variants of DNA or RNA targets, uses ThermoBLAST playlists to scan for off-target hybridizations, and scales the multiplex PCR assay design process.
• PanelPlex™-Consensus: Rigorously validated for detecting more than 1,000 bacteria, viruses, and human targets with wet-lab-validated results, the consensus design for infectious diseases leverages cloud computing. It saves an average of at least six months of iterative experimental trial-and-error optimization, produces diagnostic quality designs and automated consensus designs of multiple variants of DNA or RNA targets, uses ThermoBLAST playlists to scan for off-target hybridizations, scales the multiplex PCR assay design process, and has a massive capability.7